The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma

Cancer Cytopathology

Volumn 121, Issue 9, 2013, Pages 489-499

  Betz, Bryan L ^a   Dixon, Catherine A ^a   Weigelin, Helmut C ^a   Knoepp, Stewart M ^b   Roh, Michael H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b Saint Joseph Mercy Health System   (United States)

Author keywords

Adenocarcinoma; Anaplastic lymphoma kinase (ALK) rearrangement; Cytology; Direct smear; Fine needle aspiration; Fluorescence in situ hybridization; Lung cancer; Non small cell lung cancer; Precision medicine

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DIFF QUIK DYE; DYE; PARAFFIN; UNCLASSIFIED DRUG; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; MESSENGER RNA; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; CANCER STAGING; CELL ASSAY; CELL BLOCK; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGIC DIRECT SMEAR; CYTOPATHOLOGY; DIFF QUIK STAINING; EML4 ALK FUSION GENE; FALSE NEGATIVE RESULT; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMEAR; STAINING; ADENOCARCINOMA; ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT; CYTODIAGNOSIS; CYTOLOGY; DIRECT SMEAR; FINE-NEEDLE ASPIRATION; GENETICS; LUNG CANCER; LUNG TUMOR; NON-SMALL CELL LUNG CANCER; PRECISION MEDICINE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT; CYTOLOGY; DIRECT SMEAR; FINE-NEEDLE ASPIRATION; FLUORESCENCE IN SITU HYBRIDIZATION; LUNG CANCER; NON-SMALL CELL LUNG CANCER; PRECISION MEDICINE;

ADENOCARCINOMA; CYTODIAGNOSIS; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84887238907     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21286     Document Type: Article

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61: 69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62: 10-29.
3. International Agency for Research on Cancer, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press; 2004.
4. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21(suppl 2): S16-S22.
5. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461: 245-257.
6. Azzoli CG, Baker S Jr, Temin S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV nonsmall-cell lung cancer. J Clin Oncol. 2009;27: 6251-6266.
7. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15: 5216-5223.
8. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448: 561-566.
9. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363: 1693-1703.
10. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13: 1011-1019.
11. Knoepp SM, Roh MH. Ancillary techniques on direct-smear aspirate slides: a significant evolution for cytopathology techniques [published online ahead of print July 11, 2012]. Cancer (Cancer Cytopathol). doi: 10.1002/cncy.21214.
12. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011;136: 564-571.
13. Hookim K, Roh MH, Willman J, et al. Application of immunocytochemistry and BRAF mutational analysis to direct smears of metastatic melanoma. Cancer (Cancer Cytopathol). 2012;120: 52-61.
14. Bernacki KD, Betz BL, Weigelin HC, et al. Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study. Am J Clin Pathol. 2012;138: 670-677.
15. Zhou L, Smith D, Wittwer C. Rare allele enrichment and detection by allele-specific PCR, competitive probe blocking and melting analysis. In: BioTechniques Protocol Guide. New York, NY: Informa; 2012: 387-391. doi: 10.2144/000113783.
16. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med. 2012;136: 796-803.
17. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23: 5900-5909.
18. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98: 1817-1824.
19. Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009;27: 5080-5087.
20. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26: 5589-5595.
21. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol. 2007;2: 1086-1090.
22. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol. 2006;126: 608-615.
23. Smith GD, Chadwick BE, Willmore-Payne C, Bentz JS. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. J Clin Pathol. 2008;61: 487-493.
24. van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 2011;6: e17791.
25. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010;46: 1773-1780.
26. Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol. 2012;138: 332-346.
27. Aisner DL, Sams SB. The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities. Diagn Cytopathol. 2012;40: 511-524.